HCAT
Health Catalyst, Inc.
Health Catalyst, Inc. insider trading
Insiders at Health Catalyst, Inc. have been buying its stock on the open market. The largest purchase in the last 30 days was Kohl Simeon (Chief Executive Officer · Director) buying $105.4K of HCAT, filed Sep 16, 2026. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
- Bought on the open market
- $105.4K
- Sold
- —
- Insiders
- 1
- Latest trade
- Sep 14, 2026
From SEC filings · last 30 days
Recent HCAT insider transactions
Kohl SimeonChief Executive Officer · Director
Bought 59,000 sh at $1.79 · Sep 14, 2026
$105.4K
Filing
SEC Form 4 data, Q3 2024 to Q2 2026
HCAT insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded HCAT on the open market: 0 purchases and 33 sales worth $1.6M, 29 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 3 sales ($221.2K), by 2 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | −$200.6K2 sales · 1 on a plan | |
| Q3 2025 | — | −$20.7K1 sale · all on a plan | |
| Q2 2025 | — | −$66.8K3 sales · all on a plan | |
| Q1 2025 | — | −$299.6K7 sales · all on a plan | |
| Q4 2024 | — | −$781.7K11 sales · 10 on a plan | |
| Q3 2024 | — | −$248K9 sales · 7 on a plan |
- Largest sale
- −$175.4K of HCAT by LeSueur Daniel (Chief Operating Officer) on Dec 04, 2024, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Landry Benjamin10b5-1
General Counsel
−$72.4K
Dec 05, 2025
27,425 sh · $2.64
Larson-Green Julie
Director
−$128.2K
Dec 04, 2025
47,997 sh · $2.67
Landry Benjamin10b5-1
General Counsel
−$20.7K
Sep 05, 2025
6,175 sh · $3.35
Landry Benjamin10b5-1
General Counsel
−$23.9K
Jun 05, 2025
6,057 sh · $3.94
LeSueur Daniel10b5-1
Chief Operating Officer
−$21.4K
May 05, 2025
5,209 sh · $4.10
LeSueur Daniel10b5-1
Chief Operating Officer
−$21.6K
Apr 03, 2025
5,209 sh · $4.15
Landry Benjamin10b5-1
General Counsel
−$62.9K
Mar 06, 2025
13,827 sh · $4.55
LeSueur Daniel10b5-1
Chief Operating Officer
−$76.4K
Mar 05, 2025
16,902 sh · $4.52
Llewelyn Linda10b5-1
Chief People Officer
−$35K
Feb 18, 2025
6,441 sh · $5.43
LeSueur Daniel10b5-1
Chief Operating Officer
−$30K
Feb 05, 2025
5,209 sh · $5.76
Llewelyn Linda10b5-1
Chief People Officer
−$37.4K
Jan 15, 2025
6,442 sh · $5.80
LeSueur Daniel10b5-1
Chief Operating Officer
−$39.1K
Jan 06, 2025
5,209 sh · $7.51
Landry Benjamin10b5-1
General Counsel
−$18.8K
Jan 06, 2025
2,500 sh · $7.52
Gallagher Duncan10b5-1
Director
−$31.2K
Dec 30, 2024
4,500 sh · $6.93
Gallagher Duncan10b5-1
Director
−$31.4K
Dec 23, 2024
4,500 sh · $6.98
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 05, 2025 | Landry Benjamin10b5-1General Counsel | 27,425 | $2.64 | −$72.4K |
| Dec 04, 2025 | Larson-Green JulieDirector | 47,997 | $2.67 | −$128.2K |
| Sep 05, 2025 | Landry Benjamin10b5-1General Counsel | 6,175 | $3.35 | −$20.7K |
| Jun 05, 2025 | Landry Benjamin10b5-1General Counsel | 6,057 | $3.94 | −$23.9K |
| May 05, 2025 | LeSueur Daniel10b5-1Chief Operating Officer | 5,209 | $4.10 | −$21.4K |
| Apr 03, 2025 | LeSueur Daniel10b5-1Chief Operating Officer | 5,209 | $4.15 | −$21.6K |
| Mar 06, 2025 | Landry Benjamin10b5-1General Counsel | 13,827 | $4.55 | −$62.9K |
| Mar 05, 2025 | LeSueur Daniel10b5-1Chief Operating Officer | 16,902 | $4.52 | −$76.4K |
| Feb 18, 2025 | Llewelyn Linda10b5-1Chief People Officer | 6,441 | $5.43 | −$35K |
| Feb 05, 2025 | LeSueur Daniel10b5-1Chief Operating Officer | 5,209 | $5.76 | −$30K |
| Jan 15, 2025 | Llewelyn Linda10b5-1Chief People Officer | 6,442 | $5.80 | −$37.4K |
| Jan 06, 2025 | LeSueur Daniel10b5-1Chief Operating Officer | 5,209 | $7.51 | −$39.1K |
| Jan 06, 2025 | Landry Benjamin10b5-1General Counsel | 2,500 | $7.52 | −$18.8K |
| Dec 30, 2024 | Gallagher Duncan10b5-1Director | 4,500 | $6.93 | −$31.2K |
| Dec 23, 2024 | Gallagher Duncan10b5-1Director | 4,500 | $6.98 | −$31.4K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check HCAT — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Health Catalyst, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Are HCAT insiders buying or selling?
- Between Sep 14, 2026 and Sep 14, 2026, 1 Health Catalyst, Inc. insider made 1 open-market purchase worth $105.4K and no sales, a net purchase of $105.4K.
- How much HCAT stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 7 Health Catalyst, Inc. insiders made no open-market purchases and 33 sales worth $1.6M. 29 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 3 sales ($221.2K). The largest sale was LeSueur Daniel selling $175.4K on Dec 04, 2024.
- What was the largest recent HCAT insider trade?
- Kohl Simeon (Chief Executive Officer · Director) bought $105.4K of HCAT stock on Sep 14, 2026 at about $1.79 a share.
- When did an insider last buy HCAT shares?
- The most recent open-market purchase on file is Kohl Simeon (Chief Executive Officer · Director) buying $105.4K on Sep 14, 2026.
- Where does HCAT insider trading data come from?
- From the Form 4 filings Health Catalyst, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.